Mobile phone use and glioma risk: Comparison of epidemiological study results with incidence trends in the United States

Radiation Epidemiology Branch, National Cancer Institute, Rockville, MD 20852-7238, USA.
BMJ (online) (Impact Factor: 17.45). 03/2012; 344:e1147. DOI: 10.1136/bmj.e1147
Source: PubMed


In view of mobile phone exposure being classified as a possible human carcinogen by the International Agency for Research on Cancer (IARC), we determined the compatibility of two recent reports of glioma risk (forming the basis of the IARC's classification) with observed incidence trends in the United States.
Comparison of observed rates with projected rates of glioma incidence for 1997-2008. We estimated projected rates by combining relative risks reported in the 2010 Interphone study and a 2011 Swedish study by Hardell and colleagues with rates adjusted for age, registry, and sex; data for mobile phone use; and various latency periods.
US population based data for glioma incidence in 1992-2008, from 12 registries in the Surveillance, Epidemiology, and End Results (SEER) programme (Atlanta, Detroit, Los Angeles, San Francisco, San Jose-Monterey, Seattle, rural Georgia, Connecticut, Hawaii, Iowa, New Mexico, and Utah).
Data for 24,813 non-Hispanic white people diagnosed with glioma at age 18 years or older.
Age specific incidence rates of glioma remained generally constant in 1992-2008 (-0.02% change per year, 95% confidence interval -0.28% to 0.25%), a period coinciding with a substantial increase in mobile phone use from close to 0% to almost 100% of the US population. If phone use was associated with glioma risk, we expected glioma incidence rates to be higher than those observed, even with a latency period of 10 years and low relative risks (1.5). Based on relative risks of glioma by tumour latency and cumulative hours of phone use in the Swedish study, predicted rates should have been at least 40% higher than observed rates in 2008. However, predicted glioma rates based on the small proportion of highly exposed people in the Interphone study could be consistent with the observed data. Results remained valid if we used either non-regular users or low users of mobile phones as the baseline category, and if we constrained relative risks to be more than 1.
Raised risks of glioma with mobile phone use, as reported by one (Swedish) study forming the basis of the IARC's re-evaluation of mobile phone exposure, are not consistent with observed incidence trends in US population data, although the US data could be consistent with the modest excess risks in the Interphone study.

Download full-text


Available from: Mark P Little, Jul 22, 2014
  • Source
    • "However, a Danish study on the use of cell phones [10] performed with a large cohort of cancer patients from a national registry concluded that there was little evidence for a causal association and therefore no increased risk of CNS tumors. Another recent study by Little et al. [11] suggested that there is little evidence linking cell phone use to a higher risk for glioma. On the other hand, the researchers noted that the higher risks previously seen were not consistent with the incidence trends they found in the American population. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glioblastoma multiforme (GBM) is the most lethal subtype of glioma, classified as a WHO grade 4 infiltrative glioma. The etiology of GBM remains unknown and risk factors can be identified only in a small minority. We report the synchronous occurrence of GBM in an otherwise unrelated married couple, i.e. a husband and his wife, who developed GBM within an interval of 1 month. No specific causative environmental factors were identified for both patients, and the genetic screens were negative for hereditary syndromes. Family history was negative for tumors, and no other incidence of cancer in either siblings, parents or other children was reported. An analysis of the couple's exposure to nonionizing electromagnetic fields and ionizing radiations revealed values within the normal ranges usually found in homes. Overall, conjugal tumors are rarely reported. However, the case reported herein raises important questions about possible etiologic factors.
    Full-text · Article · Oct 2013 · Case Reports in Oncology
  • Source
    • "Personal habits such as diet, alcohol use, caffeine intake, and nicotine use have been studied, but no clear association with GB has been identified. Multiple studies have also failed to correlate cell phone usage with tumor incidence.13,14 In the past 5 years, the role of cytomegalovirus genes in malignant gliomas has been explored. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glioblastoma (GB) is one of the most lethal forms of cancer, with an invasive growth pattern that requires the use of adjuvant therapies, including chemotherapy and radiation, to prolong survival. Temozolomide (TMZ) is an oral chemotherapy with a limited side effect profile that has become the standard of care in GB treatment. While TMZ has made an impact on survival, tumor recurrence and TMZ resistance remain major challenges. Molecular markers, such as O6-methylguanine-DNA methyltransferase methylation status, can be helpful in predicting tumor response to TMZ, and therefore guides clinical decision making. This review will discuss the epidemiology and possible genetic underpinnings of GB, how TMZ became the standard of care for GB patients, the pharmacology of TMZ, the practical aspects of using TMZ in clinic, and how molecular diagnostics - particularly the use of O6-methylguanine-DNA methyltransferase status - affect clinical management.
    Preview · Article · Jan 2013 · Clinical Pharmacology: Advances and Applications
  • Source

    Full-text · Article · May 2012 · BMJ (online)
Show more